Tsukaguchi T - Search Results

1

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.

Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H. Kodama T, et al. Among authors: tsukaguchi t. Cancer Lett. 2014 Sep 1;351(2):215-21. doi: 10.1016/j.canlet.2014.05.020. Epub 2014 Jun 2. Cancer Lett. 2014. PMID: 24887559

2

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y. Sakamoto H, et al. Among authors: tsukaguchi t. Cancer Cell. 2011 May 17;19(5):679-90. doi: 10.1016/j.ccr.2011.04.004. Cancer Cell. 2011. PMID: 21575866 Free article.

3

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.

Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y. Ono N, et al. Among authors: tsukaguchi t. Cancer Sci. 2013 Oct;104(10):1346-52. doi: 10.1111/cas.12237. Epub 2013 Aug 20. Cancer Sci. 2013. PMID: 23863134 Free PMC article.

4

A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.

Kodama T, Motoi N, Ninomiya H, Sakamoto H, Kitada K, Tsukaguchi T, Satoh Y, Nomura K, Nagano H, Ishii N, Terui Y, Hatake K, Ishikawa Y. Kodama T, et al. Among authors: tsukaguchi t. J Thorac Oncol. 2014 Nov;9(11):1638-46. doi: 10.1097/JTO.0000000000000311. J Thorac Oncol. 2014. PMID: 25144242 Free article.

5

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.

Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H. Kodama T, et al. Among authors: tsukaguchi t. Mol Cancer Ther. 2014 Dec;13(12):2910-8. doi: 10.1158/1535-7163.MCT-14-0274. Epub 2014 Oct 27. Mol Cancer Ther. 2014. PMID: 25349307

6

Synthesis and structure-activity relationships of novel benzofuran farnesyltransferase inhibitors.

Asoh K, Kohchi M, Hyoudoh I, Ohtsuka T, Masubuchi M, Kawasaki K, Ebiike H, Shiratori Y, Fukami TA, Kondoh O, Tsukaguchi T, Ishii N, Aoki Y, Shimma N, Sakaitani M. Asoh K, et al. Among authors: tsukaguchi t. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1753-7. doi: 10.1016/j.bmcl.2009.01.074. Epub 2009 Feb 11. Bioorg Med Chem Lett. 2009. PMID: 19217288

7

Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.

Kinoshita K, Ono Y, Emura T, Asoh K, Furuichi N, Ito T, Kawada H, Tanaka S, Morikami K, Tsukaguchi T, Sakamoto H, Tsukuda T, Oikawa N. Kinoshita K, et al. Among authors: tsukaguchi t. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3788-93. doi: 10.1016/j.bmcl.2011.04.020. Epub 2011 Apr 22. Bioorg Med Chem Lett. 2011. PMID: 21561771

8

9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.

Kinoshita K, Kobayashi T, Asoh K, Furuichi N, Ito T, Kawada H, Hara S, Ohwada J, Hattori K, Miyagi T, Hong WS, Park MJ, Takanashi K, Tsukaguchi T, Sakamoto H, Tsukuda T, Oikawa N. Kinoshita K, et al. Among authors: tsukaguchi t. J Med Chem. 2011 Sep 22;54(18):6286-94. doi: 10.1021/jm200652u. Epub 2011 Aug 25. J Med Chem. 2011. PMID: 21823617

9

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

Kinoshita K, Asoh K, Furuichi N, Ito T, Kawada H, Hara S, Ohwada J, Miyagi T, Kobayashi T, Takanashi K, Tsukaguchi T, Sakamoto H, Tsukuda T, Oikawa N. Kinoshita K, et al. Among authors: tsukaguchi t. Bioorg Med Chem. 2012 Feb 1;20(3):1271-80. doi: 10.1016/j.bmc.2011.12.021. Epub 2011 Dec 22. Bioorg Med Chem. 2012. PMID: 22225917

10

Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.

Tanaka H, Sase H, Tsukaguchi T, Hasegawa M, Tanimura H, Yoshida M, Sakata K, Fujii T, Tachibana Y, Takanashi K, Higashida A, Hasegawa K, Ono Y, Oikawa N, Mio T. Tanaka H, et al. Among authors: tsukaguchi t. Mol Cancer Ther. 2018 Dec;17(12):2519-2529. doi: 10.1158/1535-7163.MCT-17-1180. Epub 2018 Sep 21. Mol Cancer Ther. 2018. PMID: 30242093

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page